Drug Trial Radar · NCT07874620
A Study of Cebranopadol for Opioid Withdrawal Symptoms in Adults With Chronic Pain
Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
45
Planned (sponsor's estimate)
Start
Oct 2026
Primary completion
Mar 2027
Study completion Jun 2027
Sponsor
- Lead sponsor
- Adneuris Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 2 study will evaluate whether multiple doses of cebranopadol suppress opioid withdrawal signs and symptoms compared with placebo in adults with chronic pain who are physically dependent on prescribed opioids. Participants whose physical dependence is confirmed will be assigned by chance to one of two cebranopadol dose regimens or matching placebo. The study will also evaluate pain, safety and tolerability, and cebranopadol pharmacokinetics.
Conditions
- Chronic Pain
- Pain
- Opioid Withdrawal (Disorder)
- Opioid Use Disorder
Interventions
CebranopadolDrug
Administration orally twice daily on Days 1 and 2 and according to the assigned regimen.
CebranopadolDrug
Administration orally twice daily on Days 1 and 2 and according to the assigned regimen.
PlaceboDrug
Administration orally twice daily on Day 1 and 2.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical Opiate Withdrawal Scale (COWS) Total Score Maximum Effect (Emax) from 0 to 48 hoursTime frame: From first study-drug administration through 48 hours after the first dose]
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
001127
North Canton, Ohio · Recruiting
00113
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.